Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-escalation study of oral BCX1777 in recurrent or refractory T/NK-cell malignancies
jRCT2080220654Phase 1
- Sponsor
- Mundipharma
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of forodesine in T-cell lymphoma, natural killer cell neoplasm and natural killer/T-cell lymphoma (NKTL), sponsored by Mundipharma.
02
Drugs
forodesine
03
Conditions
T-cell lymphomanatural killer cell neoplasmnatural killer/T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on jRCT2080220654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220654.